Detalhe da pesquisa
1.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Am J Hematol
; 97(5): 562-573, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132679
2.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Cancer Immunol Res
; 7(1): 100-112, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396908